Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05270213 · ClinicalTrials.gov registry record · Phase 1
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
A Phase 1 study of Advanced Cancer, sponsored by Riboscience.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 164
- Enrollment target
- 14
- Study locations
NCT05270213 is a Phase 1 study of Advanced Cancer that is actively recruiting participants, run by Riboscience. The registered enrollment target is 164 participants, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (33% lower). The trial reports 14 study locations across 11 states.
The verdict
NCT05270213, a Phase 1 study of Advanced Cancer, is actively recruiting participants, sponsored by Riboscience.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 164 participants
- Enrollment target
- 14
- Study locations
Study Summary
RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP levels) and reducing adenosine production in the tumors. RBS2418 has the potential to be an important therapeutic option for subjects both as monotherapy and in combination with other cancer treatments including monotherapy and in combination with other cancer treatments including immunotherapy or chemotherapy. This study is an open-label, multi-site Phase 1a/1b study of RBS2418, a selective ENPP1 inhibitor, in combination with pembrolizumab or other approved anticancer therapies or as a monotherapy in subjects with advanced unresectable, recurrent or metastatic tumors. The phase 1a (dose escalation phase) has been completed. The Phase 1b expansion phase of the study has been increased in size and scope.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG RBS2418
- DRUG Other approved anti-cancer therapy
Study Locations (14)
Arizona
- Honor Health Research Institute - Scottsdale
- University of Arizona - Tucson
California
- Stanford Cancer Institute - Palo Alto
- UCLA Hematology/Oncology - Santa Monica - Santa Monica
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
- American Oncology Partners of Maryland - Bethesda
Delaware
- Christiana Care Health Services - Newark
Kentucky
- Norton Cancer Institute - Louisville
Louisiana
- Ochsner Clinic Foundation - New Orleans
New York
- Ichan School of Medicine at Mount Sinai - New York
North Carolina
- Carolina BioOncology Institute - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2022-07-11 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05270213
The ClinicalTrials.gov registry entry for NCT05270213 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 245-participant average among 122 other Advanced Cancer trials with a reported enrollment target (33% lower). The listed sponsor is Riboscience, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT05270213 reports 14 study locations spanning 11 distinct geographic areas - top geographies include Arizona, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT05270213 about?
NCT05270213 is a clinical study titled "Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors". RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphospha...
What is the current status of trial NCT05270213?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 164 participants. The study started on 2022-07-11. Estimated completion is 2027-12.
What conditions does trial NCT05270213 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT05270213?
The interventions under investigation include: Pembrolizumab (DRUG), RBS2418 (DRUG), Other approved anti-cancer therapy (DRUG).
Who is sponsoring clinical trial NCT05270213?
This trial is sponsored by Riboscience, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05270213 being conducted?
This trial has 14 study locations across Arizona, California, Delaware, Kentucky, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.